An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Agile Therapeutics, Inc. (AGRX) will announce its fourth quarter and full year 2023 financial results on March 22, 2024. The company will host a live conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a business update.
Positive
None.
Negative
None.
Live Conference Call and Webcast at 8:30 a.m. ET
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update.
Event
Agile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference Call
Date
Friday, March 22, 2024
Time
8:30 a.m. ET / 5:30 a.m. PT
A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.
AboutAgileTherapeutics,Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website and LinkedIn account.
FAQ
When will Agile Therapeutics (AGRX) report its fourth quarter and full year 2023 financial results?
Agile Therapeutics (AGRX) will report its fourth quarter and full year 2023 financial results on Friday, March 22, 2024.
What time will the live conference call and webcast take place for Agile Therapeutics (AGRX) fourth quarter & full year 2023 financial results?
The live conference call and webcast for Agile Therapeutics (AGRX) fourth quarter & full year 2023 financial results will take place at 8:30 a.m. ET on March 22, 2024.
How can I access the live webcast of the conference call for Agile Therapeutics (AGRX) fourth quarter & full year 2023 financial results?
You can access the live webcast of the conference call for Agile Therapeutics (AGRX) fourth quarter & full year 2023 financial results via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations.
How can I participate in the live conference call via telephone for Agile Therapeutics (AGRX) fourth quarter & full year 2023 financial results?
To participate in the live conference call via telephone for Agile Therapeutics (AGRX) fourth quarter & full year 2023 financial results, please register on the provided link. Upon registering, you will receive a dial-in number and unique PIN to join the conference call.
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.